Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 8Terminated 5Unknown 2Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 16Recurrence 3Neoplasms, Plasma Cell 2Renal Insufficiency 1Paraproteinemias 1Neoplasms by Histologic Type 1Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Hypoxia 1High Grade Squamous Intra-epithelial Lesion (HSIL) 1Hematologic Diseases 1Disease Progression 1Blood Protein Disorders 1Amyloidosis 1

Interventions

Cyclophosphamide 16Dexamethasone 14Melphalan 12Bortezomib 11Filgrastim 6Peripheral Blood Stem Cell Transplantation 5Lenalidomide 5Thalidomide 4Prednisone 4sargramostim 3fludarabine phosphate 3daratumumab 3Radiotherapy 3Mycophenolic Acid 3Interferon-alpha 3Doxorubicin 3Busulfan 3Antilymphocyte Serum 3pomalidomide 2isatuximab 2fludarabine 2Vincristine 2Methylprednisolone 2Idarubicin 2Cyclosporine 2Carmustine 2plerixafor 1pegfilgrastim 1orantinib 1epoetin beta 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Neoplasms, Plasma Cell × pomalidomide × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Threshold Pharmaceuticals

Phase 1/2 Unknown
98 enrolled
Plasma cell

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡